(Reuters) -The European Union’s health regulator has lifted the temporary restriction on the use of French drugmaker Valneva’s chikungunya vaccine, Ixchiq, in adults aged 65 and above ...

Valneva (NASDAQ:VALN) said on Friday that the European Medicines Agency (EMA) has lifted the suspension on its chikungunya vaccine, Ixchiq, for adults aged 65 years and older. The EMA's safety ...

Side Effect Risk Groups Ixchiq was authorized in the EU in June 2024. When the recent PRAC review began, around 36,000 doses of the vaccine had been used worldwide. Safety data recorded 28 cases ...

IXCHIQ ® was authorised in the European Union in June 2024 2 and, in March 2025, the European Commission granted a label extension in adolescents 12 years of age and older 3. About Chikungunya ...

In May last year, the EMA recommended granting a marketing authorization in the EU for Ixchiq, the first vaccine in the EU to protect adults 18 years and older against chikungunya.

Guangdong province in China is grappling with a significant chikungunya virus outbreak, reporting over 7,000 cases since July ...

The chikungunya virus, which is spread by mosquitoes, is rarely fatal but has seen a surge in cases in China after an ...

A massive chikungunya outbreak in Guangdong province, southern China, has raised global alarms. Since mid-June, over 7,000 ...

Valneva and Instituto Butantan are working together to ensure fast access to its chikungunya vaccines for the Brazilian market and other countries in the region as quickly as possible. The ...